Literature DB >> 11237556

Purified recombinant A. fumigatus allergens induce different responses in mice.

V P Kurup1, J Q Xia, R Crameri, D A Rickaby, H Y Choi, S Flückiger, K Blaser, C A Dawson, K J Kelly.   

Abstract

Aspergillus fumigatus an opportunistic fungus is associated with a number of diseases in humans. Allergy resulting from exposure to the A. fumigatus allergens has been recognized frequently. The damage caused by the disease is very striking in patients with atopy and those with cystic fibrosis. Avoidance to exposure is not feasible because A. fumigatus spores are ubiquitously distributed in the environment. Hence, immunotherapeutic regimens in severe forms of A. fumigatus allergy may have a high potential. However, before such forms of therapy can be envisaged, it is essential to understand the immunopathogenesis. In the present study, we investigated the role of purified A. fumigatus allergens in the development of allergic asthma in mice. We have used four major recombinant A. fumigatus allergens in the murine model. Mice exposed to Asp f 1, f 3, and f 4 showed inflammatory changes in the lungs and airway hyperreactivity. The immune responses, including elevated serum IgE, enhanced eosinophils, recruitment in the peripheral blood and lungs, and expression of regulatory cytokines, are characteristic of a Th2 response. Asp f 6 demonstrated only a reduced response in these animals. The results suggest that the pathology induced by crude A. fumigatus extract results from the cumulative effects of the allergens and the individual responses varied considerably with different purified antigens. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237556     DOI: 10.1006/clim.2000.4993

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  22 in total

1.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

Review 2.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

3.  Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen.

Authors:  G Ramadan; B Davies; V P Kurup; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Enzymatic activities of allergen extracts from three species of dust mites and cockroaches commonly found in Korean home.

Authors:  Kyoung Yong Jeong; Chungryul Kim; Tai-Soon Yong
Journal:  Korean J Parasitol       Date:  2010-06-17       Impact factor: 1.341

Review 5.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

Review 6.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

7.  Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and -independent manner.

Authors:  Hemanth Ramaprakash; Cory M Hogaboam
Journal:  Int Arch Allergy Immunol       Date:  2009-12-16       Impact factor: 2.749

8.  Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis.

Authors:  Banani Banerjee; Kevin J Kelly; Jordan N Fink; James D Henderson; Naveen K Bansal; Viswanath P Kurup
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  Role of antibiotics and fungal microbiota in driving pulmonary allergic responses.

Authors:  Mairi C Noverr; Rachael M Noggle; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Use of a synthetic peptide epitope of Asp f 1, a major allergen or antigen of Aspergillus fumigatus, for improved immunodiagnosis of allergic bronchopulmonary aspergillosis.

Authors:  Taruna Madan; Priyanka Priyadarsiny; Mudit Vaid; Neel Kamal; Ashok Shah; Wahajul Haq; Seturam Bandacharya Katti; P Usha Sarma
Journal:  Clin Diagn Lab Immunol       Date:  2004-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.